The drug pipeline paradigm shift: who pays?
Vice-President and General Manager,
Health Benefits and Payment Solutions
Scientific breakthroughs with pharmaceutical technologies are creating a new therapeutic paradigm that is as inspiring as it is disruptive to drug coverage sustainability. New speciality drugs can cure serious disease, reduce or eliminate very challenging symptoms or even extend life; but they come with a high price tag.
This article examines the impact of this new therapeutic paradigm and underscores how a small and ever-shrinking proportion of claims is becoming responsible for an increase in benefit plan costs. This dynamic is placing urgent pressure on plan sponsors and, indeed, on the very sustainability of drug coverage in Canada overall.